Table of Contents
A single 25 mg dose of psilocybin, given alongside structured psychological support, produced measurable reductions in depression and anxiety that held for up to two years in a group of cancer patients. Those are the findings of a phase 2 trial now published in Cancer, the peer-reviewed journal of the American Cancer Society, and they add meaningful weight to a growing body of work on psilocybin-assisted care for people navigating one of life’s most difficult diagnoses.
What the Trial Found
The study enrolled 28 people with cancer who also met criteria for major depressive disorder. Each participant received psychological support from a therapist before, during, and after a single administration of 25 mg psilocybin. Two years later, researchers conducted clinical interviews to assess lasting outcomes.
- 15 of 28 patients (53.6%) showed a significant reduction in depression at the two-year mark.
- 14 of 28 (50%) met criteria for both sustained depression reduction and full remission.
- 12 of 28 (42.9%) showed sustained reduction in anxiety at two years.
Lead author Manish Agrawal, MD, of Sunstone Therapies, described the scope of the finding plainly: “One dose of psilocybin with psychological support to treat depression has a long-term positive impact on relieving depression for as much as 2 years for a substantial portion of patients with cancer.”
How Does One Psilocybin Dose Produce Such Long-Lasting Relief?
The trial was not designed to isolate the biological mechanism, so this question remains open. What the data show is that the compound, when held within a therapeutic container, produced effects that outlasted the session itself by many months. The researchers do not claim to know exactly why. The combination of the pharmacological experience and sustained psychological support before and after the dose appears to be a meaningful part of the picture, though the relative contribution of each element is still being studied.
What Comes Next
An ongoing randomized, double-blind trial is now evaluating up to two doses of 25 mg psilocybin versus placebo in cancer patients with depression and anxiety. The goal, as Agrawal noted, is to explore whether a repeated treatment brings a larger share of patients into remission. The phase 2 results presented here are promising, but the sample size of 28 is small, and no placebo comparison was included. These findings are best understood as hypothesis-generating, pointing toward directions that larger, controlled trials can now test more rigorously.
“If randomized testing shows similar results, this could lead to greater use of psilocybin to treat depression in patients with cancer.” – Manish Agrawal, MD, Sunstone Therapies
Held in the Dark, Something Endures
There is something worth sitting with in that two-year horizon. A single carefully held encounter with psilocybin, surrounded by human support, and its effects continue to move through a person long after the session ends. That is not magic in the dismissive sense. It is a reminder that the work done in one concentrated moment of opening can take root and grow in the ordinary time that follows.
For people with cancer, the weight of mortality is not abstract. It is present. The fact that psilocybin, in a therapeutic setting, appears to ease that particular kind of suffering, not by numbing it but by shifting something fundamental in how a person relates to their own experience, is worth profound attention.
We hold these findings with care. Fifty percent remission from a single dose in a small trial is not a conclusion. It is an invitation to look more carefully, to fund more rigorous work, and to ask what it means to accompany a person through the hardest passage of their life with the full spectrum of tools available to us.
If this research touches something in you, whether you are walking alongside illness yourself or supporting someone who is, we welcome you into our community of honest inquiry. The Integration station of the Golden Path is where science and inner life meet, where what is experienced becomes something lived and understood. Come as you are.
May love guide the hearts of all beings.
